^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | NXP900 (Src kinase inhibitor, YES1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
3326 / 4 - Uncovering the molecular mechanisms which predict sensitivity to a novel src kinase inhibitor NXP900 to inform personalized healthcare strategies
Published date:
03/09/2022
Excerpt:
Among the most sensitive cell line subtypes are, squamous cell carcinoma, Arid1A mutant ovarian clear cell carcinoma and subtypes of breast luminal A and triple negative breast cancer cell lines. HER2+ breast cancer lines appear insensitive to NXP900 indicating HER2 as a potential driver of resistance to NXP900....Our result provide an indication of patient subgroups which may exhibit optimal therapeutic response to NXP900...
